指南与共识肺外科

2026 AATS 专家共识:N2 阳性非小细胞肺癌的评估与管理

The 2026 American Association for Thoracic Surgery Expert Consensus Document: Evaluation and management of N2+ non-small cell lung cancer.
指南 / 共识 · J Thorac Cardiovasc Surg · 2026-05-02

美国胸外科协会临床实践标准委员会组建国际多学科专家组,经聚焦文献综述与改良 Delphi 法,就潜在可切除 N2 阳性非小细胞肺癌的评估与治疗达成 13 条专家共识。共识涵盖分期、不可切除判定、化疗免疫或靶向治疗、新辅助与辅助治疗、再分期及化疗免疫后手术安全性。

要点

  • N2 阳性 NSCLC 推荐多模式治疗,免疫检查点抑制剂与靶向治疗已改变治疗格局。
  • 共识共 13 条,覆盖分期、不可切除因素、围术期治疗与再分期。
  • 目标在于筛选合适手术患者并制定最佳多模式治疗方案。

核心结论

  • N2 阳性 NSCLC 仍是具有挑战性的异质性疾病,共识为筛选合适手术患者和制定最佳多模式治疗提供指导。

研究设计与样本

  • 美国胸外科协会临床实践标准委员会组建国际专家组,成员包括肿瘤内科、放疗科、放射科和胸外科医师,经医学图书馆员协助完成聚焦文献综述,采用改良 Delphi 法制订带推荐等级和证据级别的专家共识声明。

主要发现

  • 专家组就分期、不可切除疾病的决定因素、化疗免疫治疗或靶向治疗的使用、新辅助和/或辅助治疗的合理应用、再分期以及化疗免疫治疗后切除的安全性等主题达成 13 条共识。

临床怎么用

  • 用于识别适合手术的 N2 阳性 NSCLC 患者,并指导其多模式治疗的制定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Multimodal therapy is recommended for the optimal treatment of N2 positive non-small cell lung cancer (NSCLC). Recent advancements in the use of immune checkpoint inhibitors and targeted therapy have dramatically changed the landscape of treatment. We reviewed recent trials and literature to develop consensus statements concerning the evaluation and treatment of potentially resectable NSCLC with N2 involvement. METHODS: The American Association for Thoracic Surgery Clinical Practice Standards Committee assembled an international panel of medical oncologists, radiation oncologists, radiologists, and thoracic surgeons. A focused literature review was performed with the assistance of a medical librarian. The panel used a modified Delphi method to develop expert consensus statements with class of recommendation and level of evidence on issues related to the treatment of potentially resectable N2 positive NSCLC. RESULTS: Consensus was reached on 13 statements on topics related to staging, determinants of unresectable disease, use of chemoimmunotherapy or targeted therapies, proper use of neoadjuvant and/or adjuvant therapy, restaging, and the safety of resection after chemoimmunotherapy. CONCLUSIONS: NSCLC with N2 disease remains a challenging, heterogeneous disease. These expert consensus recommendations are meant to provide guidance to identify appropriate surgical patients and to formulate the best multimodality treatment of patients with N2-positive NSCLC.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Linden PA, Martin LW, Stiles B, et al. The 2026 American Association for Thoracic Surgery Expert Consensus Document: Evaluation and management of N2+ non-small cell lung cancer. J Thorac Cardiovasc Surg. 2026. PMID: 42081972. doi:10.1016/j.jtcvs.2026.03.622

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。